Piotr Tomczak - Researcher Profile | RDL Research Database

Publications

2 shown

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien , Nely Wigler , Moshe Inbar +11 more

2004 Annals of Oncology 1672 citations

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer , Thomas E. Hutson , Piotr Tomczak +11 more

Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa ...

2007 New England Journal of Medicine 5691 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 7,363
Institution: Hematology\Oncology Clinic

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-8816-5525

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.